피씨엘
6,040KRWMarket close of 10/27 (Tue)
No trade that dayMarket close of 10/27 (Tue)
Preliminary value — replaced once official KRX data for the same date is publishedClose of 10/28 (Wed)6,040KRWFlat 0.00%
Preliminary · replaced once official KRX data for the same date is published
- Volume
- 0×10K shares
- 0 KRW
Open, high and low are not shown — the source has no bar for the reference date
Market close of 10/27 (Tue)
Where it sits in the 1-year range
0%0% of the way up from the lowest close in 1 year (252 sessions) · -85.1% from the high
Free · no sign-inSource from 2021-05-17
Points to check
- Daily moveto checkNo trades this day (0 shares)
- Earningsto check-21.3B KRWOperating income over the last four quarters -21.3B KRW (loss)
- Trading valuenot verifiedNo trading that day, so not compared with usual trading value
The other 2
- Recent filingsnot verified
- Foreign & institutionalnot verified
See the full check report
Quarterly results · Q3 2025
- Revenue1.2B KRW
- vs. year ago
- +217.4%
- vs. prior quarter
- -28.1%
- Operating income127.34 million KRW
- vs. year ago
- Turned profitable
- vs. prior quarter
- Turned profitable
- Operating margin10.6%
- vs. year ago
- +618.4 pp
- vs. prior quarter
- +258.1 pp
Quarterly operating income trend
As of the latest official close · 2026-10-27Valuation filing date · 2025-11-14Same sector · 제약
Down -2.22%· 88 of 168 stocks up, preferred shares excluded · trading value 553.0B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 삼성바이오로직스 | Close over the last 20 sessions +0.6% | Down -5.37% | 124.5B KRW |
| 셀트리온 | Close over the last 20 sessions +6.3% | Down -0.74% | 82.4B KRW |
| 지투지바이오 | Close over the last 20 sessions +22.2% | Down -13.38% | 46.9B KRW |
| 한미약품 | Close over the last 20 sessions -32.6% | Down -0.57% | 25.5B KRW |
| 에스티팜 | Close over the last 20 sessions -11.9% | Down -9.15% | 21.4B KRW |
Schedule
- Next data 10/29 (Thu) after 08:50
Related news
Tables, financials, investor flows and filing history are in the Detailed view.
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 82% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.